Latest Threads

A meeting for Amlak Finance PJSC is scheduled for Thursday, 29 May 2025, at 3:30 PM. The agenda includes discussing the execution of the sale of the company's plots in Ras Al Khor, convening a General Meeting to address transferring the balance of the Legal and Special Reserves as of December 31, 2024, to partially offset accumulated losses, approving the company's exit from the real estate finance portfolio through various means, and discussing normal business activities and updates. The authorized signatory for this meeting is Lama Takieddin, Head of Corporate Governance and Company Secretary.

The settlement price for Micro GME Oman Crude Oil Futures contracts expiring in May 2025 is $63.26 USD, with the contract series code OMOIL N25 and contract ID OIL230525001. This information was issued on May 23, 2025, and is available on the Dubai Financial Market website. The document includes a disclaimer noting that the information is subject to change and emphasizes that it does not replace the official Dubai Financial Market Regulated Derivative Contract Trading Regulation.

The weekly summary for Dubai Financial Market (DFM) Regulated Short Sell Transactions from May 19 to May 23, 2025, reports that Parkin Company PJSC had a short sell trade volume of 6,000 and a trade value of AED 39,800. For more details on Regulated Short Selling, refer to the DFM Market Rules and related documents available on their website. The announcement and further information can also be accessed online. The document includes a disclaimer noting that the information is subject to change and DFM is not liable for any losses incurred from its use.

Globalpharma, a leading pharmaceutical manufacturer in the UAE, has signed four strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. These agreements aim to strengthen the UAE's position as a hub for pharmaceutical innovation and advanced healthcare manufacturing. The MoUs involve collaborations with PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada), focusing on technology transfer, product licensing, supply, and local manufacturing. These partnerships align with the UAE's industrial strategy to boost domestic production, reduce import dependence, and enhance access to next-generation healthcare solutions. The agreements reflect the UAE's commitment to empowering local industry, accelerating innovation, and establishing the country as a global hub for high-quality healthcare solutions. Specific collaborations include PharmaPrimes Laboratories working on biosimilar drug capabilities in the UAE and Nerhadou International introducing a range of nutraceutical and OTC products tailored to regional health needs.